ConductScience.org, home

Paper39256296

Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.

Tan S and 8 others. Cardiovasc Toxicol, 2024. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review. Papers, record 39256296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39256296

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.
PubMed
Journal
Cardiovasc Toxicol
PubMed
Year
2024
PubMed
Publication types
Case Reports, Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
1.44, provisional
iCite
Revised in PubMed
2026-07-23
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tan SSihan
2Qi CChang
3Zeng HHao
4Wei QQi
5Huang QQin
6Pu XXin
7Li WWeimin
8Li YYalun
9Tian PPanwen

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immune Checkpoint InhibitorsMajor topic
InfliximabMajor topic
Lung NeoplasmsMajor topic
MyocarditisMajor topic
Humans
Carcinoma, Non-Small-Cell Lung
Drug Resistance
Interleukin-6
Treatment Outcome
Tumor Necrosis Factor-alpha
Interleukin-6 Inhibitors

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
92159302National Natural Science Foundation of ChinaPubMed
82072598National Natural Science Foundation of ChinaPubMed
2022ZDZX0018Science and Technology Project of Sichuan, ChinaPubMed
ZYGD220091-3-5 project for disciplines of excellencePubMed
ZYJC210521-3-5 project for disciplines of excellencePubMed

Source PubMed

Download CSV of grants

References93

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128363334Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.Drug Resist Updat2017https://conductscience.org/library/papers/28363334PubMed
234724392Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.J Clin Oncol2021https://conductscience.org/library/papers/34724392PubMed
329162153Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J Immunother Cancer2017https://conductscience.org/library/papers/29162153PubMed
426765102Immune-related adverse events with immune checkpoint blockade: a comprehensive review.Eur J Cancer2016https://conductscience.org/library/papers/26765102PubMed
529802219Immune Checkpoint Inhibitor-Associated Myocarditis.Oncologist2018https://conductscience.org/library/papers/29802219PubMed
635692863Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives.Precis Clin Med2021https://conductscience.org/library/papers/35692863PubMed
736270461Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2022https://conductscience.org/library/papers/36270461PubMed
834172516Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.J Immunother Cancer2021https://conductscience.org/library/papers/34172516PubMed
932135517NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.J Natl Compr Canc Netw2020https://conductscience.org/library/papers/32135517PubMed
1029442540Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol2018https://conductscience.org/library/papers/29442540PubMed
1131011325Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.Case Rep Oncol2019https://conductscience.org/library/papers/31011325PubMed
1233785062Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series.Cardiooncology2021https://conductscience.org/library/papers/33785062PubMed
1333298621Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.J Immunother Cancer2020https://conductscience.org/library/papers/33298621PubMed
1438158463Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis.Intern Emerg Med2024https://conductscience.org/library/papers/38158463PubMed
1537305530Drug therapy for myocarditis induced by immune checkpoint inhibitors.Front Pharmacol2023https://conductscience.org/library/papers/37305530PubMed
1631285688Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.Curr Oncol2019https://conductscience.org/library/papers/31285688PubMed
1732425357Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.Ann Oncol2020https://conductscience.org/library/papers/32425357PubMed
1832093854Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.J Thorac Oncol2020https://conductscience.org/library/papers/32093854PubMed
1935399037[Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report].Zhonghua Xin Xue Guan Bing Za Zhi2022https://conductscience.org/library/papers/35399037PubMed
2036712142Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure.J Clin Case Rep2019https://conductscience.org/library/papers/36712142PubMed

See all 93 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42905219Cardiovascular Toxicity Across the Cancer Immunotherapy Spectrum: Mechanisms and Management in Immune Checkpoint Inhibitor (ICI) and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.Curr Oncol Rep2026https://conductscience.org/library/papers/42905219PubMed
42839683A serum proteomics-based predictive model for steroid-resistant immune checkpoint inhibitor associated myocarditis.Clin Transl Med2026https://conductscience.org/library/papers/42839683PubMed
42591858Immune checkpoint inhibitor-induced cardiotoxicity: from immune mechanisms to clinical surveillance and targeted therapies.Front Cardiovasc Med2026https://conductscience.org/library/papers/42591858PubMed
42499498Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management.Front Pharmacol2026https://conductscience.org/library/papers/42499498PubMed
41716314Immunotherapy-related cardiovascular toxicity: from mechanisms to management.Front Pharmacol2026https://conductscience.org/library/papers/41716314PubMed
41479885Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats.Front Immunol2025https://conductscience.org/library/papers/41479885PubMed
41373794Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review.Int J Mol Sci2025https://conductscience.org/library/papers/41373794PubMed
41141066Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Concern for 3-Ms Syndrome in a Patient With Metastatic Melanoma: A Case Report.Cureus2025https://conductscience.org/library/papers/41141066PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39256296

GET https://conductscience.org/api/papers/v1/39256296/references?page=2